Biotechnology Research Reports Precision Medicine Market Size | Page 2

a shift from chemotherapy to precision medicine. Furthermore, The University of Southampton in Britain is conducting a phase 2 clinical trial in 2017 for testing whether the addition of acalabrutinib to R-CHOP could improve outcomes of patients with diffuse large B-cell lymphoma (DLBCL) and then the trial researchers will gather the data on gene expression of DLBCL patients as a part of precision medicine for aggressive lymphoma consortium that supports the growth of precision medicine in hematology in near future. Request sample copy of this Report, https://www.coherentmarketinsights.com/insight/request-sample/145 Manufacturers are also collaborating to strengthen their product portfolios related to precision medicine. Precision for Medicine, Inc., in 2016, signed a deal to acquire ACT Oncology, which is expected to strengthen the company’s position in personalized cancer clinical trial space. On August 2017, Variantyx, a genetic testing company announced a partnership with FDNA, which has a facial recognition software that has revolutionized the diagnosis method of the rare diseases and is expected to fulfill the demand of patients and offer them precision medicine. Alexion Pharmaceuticals announced a partnership with Sema4 on August 2017, to improve the company’s diagnosis rate of the rare diseases and also speedup drug discoveries in near future. Precision for Medicine Group, Inc. acquired the Agility Clinical, a contract research organization, on September 2017, which focuses on clinical development of rare diseases and orphan therapies. This acquisition is expected to bring new precision medicine in the market. Nevertheless, lack of reimbursement policy is expected to act as a restraint for the growth of precision medicine market. To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/precision-medicine-market-145 Key Takeaways of the Market: The global precision medicine market is expected to exhibit a CAGR of 9.9% over the forecast period (2017–2025), owing to the significant adoption rate of precision medicines and the robust advancements in the industry Asia Pacific is expected to exhibit a high growth rate, in terms of value, over the forecast period Among application type, oncology segment is expected to exhibit a significant CAGR of 10.4% The global precision medicine market is characterized by market expansion in Asia Pacific, North America, and Europe, which is expected to generate higher market revenue